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ABSTRACT 
 
The medical device industry is highly profitable and projected to experience double digit growth 
well into the future. The five top performing American medical device companies offshore some 
core and non-core value chain activities to realize lower production costs, higher innovation, and 
faster time to market. This case examines the offshoring decision of Acesco Medical Devices - a 
medium-size company that produces neurology, orthopedics, and cardiovascular products. It 
considers the tradeoffs between corporate social responsibility, as it pertains to workforce 
reductions in the United Sates, and the substantial strategic benefits of offshoring to India. 
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INTRODUCTION 
 
im Fraser pondered the proposal to relocate some of Acesco Medical Devices, Inc’s activities to India. 
There are compelling cost savings and attractive new market opportunities from offshoring, but the 
prolonged U.S. recession and dour domestic political mood are reasons for caution. In particular, exporting 
high paying R&D and manufacturing jobs could be construed as yet another example of corporate greed. 
Nevertheless, recent developments in the industry’s competitive and external environments offer powerful reasons 
to do so. Any decision must balance corporate social responsibility as it pertains to job loss in the U.S. against 
considerable benefits from offshoring. 
 
Exhibit 1:  Financial Data for Selected Medical Device Firms Engaging in Offshoring (2008-2012) 
 2008 2009 2010 2011 2012 
Sales ––––––––––––––––––––––––––– $ millions –––––––––––––––––––––––––––––– 
Johnson & Johnson 63,747 61,897 61,587 65,030 67,224 
General Electric 112,769 103,777 100,437 94,523 100,149 
Siemens 77,327 76,651 75,978 73,275 78,296 
Medtronic, Inc. 13,515 14,599 15,817 15,933 16,184 
Baxter International 12,348 12,562 12,843 13,893 14,190 
Net Profit 
Johnson & Johnson 12,949 12,266 13,334 9,672 10,514 
General Electric 17,410 11,025 11,644 14,151 13,641 
Siemens 5,886 2,497 4,068 6,321 4,590 
Medtronic, Inc. 2,231 2,169 3,099 3,096 3,617 
Baxter International 2,014 2,205 1,420 2,224 2,326 
Net Worth 
Johnson & Johnson 42,511 50,588 56,579 57,080 64,826 
General Electric 104,665 117,291 118,936 116,438 123,026 
Siemens 27,380 27,287 29,096 32,156 31,302 
Medtronic, Inc. 11,536 12,851 14,629 15,968 17,113 
Baxter International 6,229 7,191 6,567 6,585 6,938 
Pretax Profit/Sales –––––––––––––––––––––––––––––––– % ––––––––––––––––––––––––––––––– 
Johnson & Johnson 26.6 25.5 27.5 19.0 20.5 
General Electric 17.0 10.0 14.1 21.3 17.4 
Siemens 3.7 5.1 7.6 13.1 9.3 
Medtronic, Inc. 21.3 17.8 25.1 23.4 25.6 
Baxter International 19.8 21.8 14.7 20.2 20.4 
Source:  Company Annual Financial Statements 
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The global medical device industry is lucrative with 2012 revenues of $350 billion that are expected to 
grow to $440 billion by 2018. The U.S. is the largest medical device market with 2012 sales of $120.4 billion 
projected to grow to $156.8 billion in 2018. The top thirty-two American companies each enjoy more than $1 billion 
in annual revenue and account for approximately 40% of the world market (Frost and Sullivan, 2012). American 
firms also face favorable domestic developments, such as a burgeoning number of Baby Boomers who consume 
significant amounts of healthcare, especially in the later stages of life; strong sales despite the prolonged recession; 
and increased demand driven by the large number of newly insured under Obamacare. The industry is lucrative and 
firms, engaged in offshoring experienced strong performance (Exhibit 1). 
 
COMPANY BACKGROUND 
 
Acesco Medical Devices, Inc. is an original equipment manufacturer focused on the neurology, 
orthopedics, and cardiovascular segments. All three exhibited double digit growth rates that are expected to continue 
into 2018 (Transparency Market Research, 2012). The company, lagging industry trends, manufactures exclusively 
within the United States. By using Food and Drug Administration (FDA) approved domestic contractors to create 
components and subassemblies. Acesco reduces costs and time-to-market. This frees it to focus on developing new 
and innovative products - an increasingly important competitive dimension. Additionally, domestic contractors tend 
to be more reliable and trustworthy than foreign counterparts. Some firms contracting with Chinese manufacturers 
experienced catastrophic quality control issues and technology leakage (Sun, 2012). Despite those advantages, as 
product designs become standardized and foreign markets become more attractive, offshoring becomes a 
competitive necessity. Foreign subcontractors not only offer cost and time savings but also bring deep knowledge of 
the regulatory environment in their home markets and the markets they sell to. 
 
Although Acesco’s performance is strong, recent developments pose uncertainties for the U.S. market. The 
Patient Protection and Affordable Care Act of 2010 will impose a 2.3% excise tax, effective in 2013, on total 
company revenues, regardless of profitability. In other words, a firm may incur losses and still be liable for the 
excise tax. Proposed reforms to the FDA-approval process, expected to hamper innovation and raise costs, will 
cause firms to locate some activities in countries with lower labor costs and favorable regulation. Furthermore, 
increasingly stringent Medicare reimbursement requirements, smaller reimbursements, and other cost-cutting 
pressures will make emerging markets, such as Brazil and China, attractive (Bain and Company, Inc., 2012). 
 
MEDICAL DEVICE INDUSTRY SWOT ANALYSIS 
 
Strengths 
 
Research Infrastructure and Venture Funding 
 
Medical research and teaching institutions in the U.S. rank among the best in the world. There are 141 
accredited medical schools, approximately 350 major teaching hospitals, and 51 Veterans Affairs medical centers 
(Association of American Medical Colleges, 2013). Close collaboration between research labs, hospitals and venture 
capitalists has helped rapidly commercialize innovations. Indeed, recent landmark technologies, such as implantable 
cardiac defibrillators, arose from such collaboration (National Venture Capital Association, 2013). 
 
Market Size and Strength of American Companies 
 
The U.S. is the largest market for medical devices with sales of $120.4 billion in 2012. The top thirty-two 
American companies each enjoy more than $1 billion in annual revenue. Additionally, American companies 
dominate the $350 billion global medical device industry with approximately 40% of the market (Frost and Sullivan, 
2012). 
 
Consumer Trends 
 
The ubiquity of mobile devices, such as smartphones and tablets, is driving the consumerization of medical 
devices. With medical associations and health care providers posting information on the Web, patients are now 
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making treatment decisions in conjunction with healthcare providers. This trend creates opportunities for medical 
companies that can produce new devices and the necessary software to streamline transfer of diagnostic results to 
Internet and mobile reporting platforms (West, 2012). 
 
Weaknesses 
 
Regulation 
 
A recent study comparing the FDA and European Medicines Agency (EMA) device approval processes 
reported that the FDA’s complex regulation and excessive bureaucracy hindered innovation and decreased American 
firms’ competitiveness in the global marketplace. The study noted that the FDA review process is almost twice as 
long as that of the EMA with a six-month mean review time in the U.S. compared to three months in Europe. Short 
review times are important because regulatory requirements play a significant role in manufacturers’ decisions to 
develop new products. Firms in countries with simpler and more efficient regulatory approval processes are quicker 
to market and reap first mover advantages (Boston Consulting Group, 2012). 
 
Shrinking STEM Pool 
 
The U.S. faces a substantial dearth of individuals with science, technology, engineering, and math skills 
(STEM). This shortfall is partly offset by the 85,000 H1B visas offered to foreign nationals with STEM backgrounds 
(Microsoft, Inc., 2013). The I-Squared or Immigration Innovation Act proposes to raise the cap to 115,000 visas 
with annual increases to a maximum of 300,000. The bill is currently generating substantial controversy because of 
persistent U.S. underemployment. 
 
No Permanent R&D Tax Credit 
 
The R&D Tax Credit offers companies an incentive to invest in high risk research that may result in viable 
products many years in the future. In its current form, the R&D tax credit has been temporarily extended since 1981. 
Historically it has generated $2 of economic growth for every $1 granted, created high paying jobs, increased 
productivity, and established the foundation for American competitiveness in a variety of global industries. Prior to 
1991, the United States was preeminent among OECD nations in the effectiveness of the R&D tax credit but by 
2008 had fallen to 17th. Many countries worldwide use permanent tax incentives to encourage domestic R&D. This 
tax credit creates an advantage for foreign firms (Deloitte, Touche, Tohmatsu Limited, 2013). 
 
Opportunities 
 
Burgeoning and Aging Populations 
 
The U.S. population is mature with a median age of 36.9 years and 13.1% of the population 65 and over 
(U.S. Census Bureau, 2012). Other developed, high-income economies are also aging. Japan, for example, has a 
median age of 45 with 22.9% of the population age 65 and over (Japan Statistical Yearbook, 2012). The global 
population is projected to rise to 9 billion by 2050. Of this number, 15% or 1.35 billion people will be age sixty and 
over (United Nations Department of Economic and Social Affairs Population Division, 2004). This bodes well for 
the industry because the elderly consume a disproportionate amount of health care resources. 
 
Emerging Economies 
 
Emerging markets will become more important as U.S. regulations and increasingly stringent Medicare 
reimbursements erode margins. As emerging economies prosper and their populations age, demand will increase 
(Transparency Market Research, 2012). In addition, less stringent regulations in Brazil and India will likely cause 
the medical device industry to follow the model of consumer product firms which use emerging markets as a 
laboratory to develop low cost products that are subsequently sold in a large number of other markets. 
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Threats 
 
Medical Reimbursements 
 
Reimbursements, which comprise a large percentage of revenue for medical device manufacturers, are 
expected to become more difficult to obtain. As employers, governments, and private party payers shift a larger 
percentage of healthcare costs to individuals and providers, device manufacturers will likely experience a decline in 
revenue (White & Ginsburg, 2012). In contrast, emerging economies, such as Brazil, India, and China, are expected 
to offer easier reimbursement terms. 
 
Shifts in Venture Industry Focus 
 
Many medical technology innovations are incubated in startups that are later acquired by established 
companies with resources to implement large-scale rollouts. Emerging markets are increasingly attractive to 
American venture capital because of higher economic growth rates, a strong desire for external investment, and 
favorable regulation. The U.S. market is less attractive because of complex and cumbersome regulations, difficulty 
in obtaining reimbursements, and an administration that favors greater regulation. Emerging markets, such as China 
and India, offer stronger growth, a comparatively streamlined medical device approval process requiring less time 
and money and large talent pools with vital STEM skills. It is likely that growing venture investments outside the 
U.S. will give rise to many startup device manufacturers that will be acquired by large medical device companies 
seeking to fill their product pipelines (National Venture Capital Association, 2013). 
 
OFFSHORING IN INDIA 
 
India offers a large pool of technical talent with over 300,000 engineers and 150,000 software developers 
graduating every year. Those engineers, paid an average of 18.3% of an American counterpart, represent a 
substantial cost advantage to firms engaged in offshoring (Pore, et al, 2008). India’s highly educated, English 
speaking labor force is also able to develop software solutions, create new hardware designs, and engage in research 
and development. They are also likely to create integrated software platforms that facilitate transfer of diagnostic 
results from medical devices to Internet or mobile platforms used by patients. Industry experts believe that 
delegating product development, design, and manufacturing to contractors or foreign subsidiaries will reduce costs, 
truncate the product development cycle, and shorten time-to-market. 
 
Offshoring Political Considerations 
 
Although the savings and competitive advantages from offshoring are considerable, Fraser understood that 
the sluggish post-2008 economy put the nation in a dour mood. Public debate over corporate America’s greed, 
hollowing out of the nation’s industrial base, and strong corporate performance despite anemic job growth, are 
reasons for concern. Offshoring, coincidentally, would require Acesco to temporarily locate some foreign 
researchers and engineers to the U.S. where they would be trained by workers they are replacing. The company 
would likely face negative publicity that could tarnish its reputation and potentially invite a backlash. 
 
Exhibit 2:  U.S. Employment in Selected Manufacturing Industries (2006-2012) 
 U.S. Labor Force Computer and Electronic Products Electrical Equipment and Appliances 
(000s) % (000s) % (000s) % 
2006 144,417 100.0 1,307.5 100.0 432.7 100.0 
2007 146,050 101.1 1,272.5 97.3 429.4 99.2 
2008 145,373 100.6 1,244.2 95.1 424.3 98.0 
2009 139,894 96.8 1,136.9 86.9 373.6 86.3 
2010 139,077 96.3 1,094.6 83.7 359.5 83.1 
2011 139,882 96.8 1,103.5 84.3 366.1 84.6 
2012 142,469 98.6 1,093.7 83.6 370.1 85.5 
Source:  Bureau of Labor Statistics, data not seasonally adjusted 
 
American job losses have fallen disproportionately on manufacturing and despite improved employment in 
2012, manufacturing still lagged behind the overall economy. Exhibit 2 compares changes in employment between 
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2006 and 2012. Overall U.S. employment is compared to that of two high margin manufacturing industries-
computers and electronics (C&E) and electrical equipment and appliances (E&A). An examination of the post-2008 
crash shows overall U.S. employment in 2009 fell 3.2% relative to the 2006 baseline. During the same period, 
employment in C&E declined 13.1% while E&A fell 13.7%. By 2012, overall U.S. employment was just 1.4% lower 
than 2006 while C&E declined 16.4% and E&A fell 14.5%. 
 
Although conventional wisdom asserts that job losses in manufacturing would be offset by new jobs 
created in the service sector, it presents an incomplete picture of the impact on workers. Exhibit 3 depicts earning 
patterns of American workers who lost jobs between January 2009 and December 2011 and subsequently found 
employment in 2012. Of the 3,003,000 unemployed workers, 630,000 (20.9%) found jobs that paid 20% or less than 
their previous wage; 538,000 (17.9%) found jobs with wages equal or above, but within 20% of their previous 
salary, and 352,000 (11.7%) were hired at 20% or more than their previous income. The picture for durable goods 
manufacturing - the category that encompasses medical devices - is less favorable. Of 457,000 workers who lost 
jobs, 125,000 (27.3%) found jobs that paid 20% or less than their former wage; 53,000 (11.5%) found jobs equal or 
above, but within 20% of their pre-unemployment wage; and 48,000 (10.5%) were hired at 20% or more than their 
prior wage. The numbers suggest that workers in durable goods manufacturing did not fare as well as the average for 
all employment categories. 
 
With U.S. manufacturing employment lagging behind the overall economy, high profits, buoyant device 
company stock prices, and substantial strategic advantages from offshoring, Fraser’s decision must tread a careful 
path between future opportunities and corporate social responsibility. 
 
Exhibit 3:  Displaced U.S. Workers (1) Who Lost Full-Time, Tenured* Wage and Salary Jobs between  
January 2009 & December 2011 and were Re-employed in January 2012 by Industry  
of Lost Job and (2) Earnings Level of New Job (1,000’s) 
Industry Of Worker Of Lost 
Job 
Total 
20%Or More 
Below 
Below, But 
Within 20% 
Equal Or Above, 
But Within 20% 
20% Or More 
Above 
Total Who Lost Full-Time 
Wage & Salary Jobs 
3,003 630 408 538 352 
Mining, Quarrying, and Oil and 
Gas Extraction 
15 12 --- --- --- 
Construction 393 89 49 64 43 
Manufacturing 645 171 108 87 64 
Durable Goods 457 125 74 53 48 
Nondurable Goods 188 46 34 34 16 
Transportation and Utilities 139 22 26 15 20 
Wholesale and Retail Trade 368 84 42 77 52 
Information 95 27 14 8 10 
Financial Activities 255 52 29 46 27 
Professional and Business 
Services 
373 56 60 93 36 
Education and Health Services 257 29 30 67 21 
Leisure and Hospitality 174 25 17 31 22 
Other Services 91 20 10 18 11 
Government Wage and Salary 
Workers 
138 30 13 22 33 
Source:  Bureau of Labor Statistics, data not seasonally adjusted.  *Tenured refers to 3 or more years on job lost because of plant 
or company closing, insufficient work, or abolition of position or shift. 
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